Use of botulinum toxin A in children with cerebral palsy.
[BACKGROUND] For more than 20 years, intramuscular injections of botulinum toxin A have been an established treatment for spasticity in children with cerebral palsy.
- p-value p < 0.001
APA
Ross Raftemo AE, Mahendran A, et al. (2019). Use of botulinum toxin A in children with cerebral palsy.. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 139(8). https://doi.org/10.4045/tidsskr.18.0554
MLA
Ross Raftemo AE, et al.. "Use of botulinum toxin A in children with cerebral palsy.." Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, vol. 139, no. 8, 2019.
PMID
31062563
Abstract
[BACKGROUND] For more than 20 years, intramuscular injections of botulinum toxin A have been an established treatment for spasticity in children with cerebral palsy. We investigated the proportion of children with cerebral palsy who receive such treatment in Norway and the guidelines that apply to the treatment.
[MATERIAL AND METHOD] Data from the five-year registration in the Cerebral Palsy Registry of Norway were used to investigate the proportion of children with cerebral palsy born in the period 1999-2010 treated with botulinum toxin A, and whether there were any variations in the proportion of children treated between the habilitation centres. We conducted an online survey to identify the treatment guidelines that were applied in all of the 21 habilitation centres.
[RESULTS] A total of 1 414 children (average age 6.3 years) were included, of whom 775 (55 %) had been treated with botulinum toxin A. The proportion of children who received treatment varied considerably between the habilitation centres (38-80 %; p < 0.001). The maximum dose of botulinum toxin A per treatment per patient was 200-600 units of Botox. Five centres reported to have written guidelines for the treatment indication.
[INTERPRETATION] The proportion of children with cerebral palsy who are treated with botulinum toxin A varies considerably between Norwegian habilitation centres.
[MATERIAL AND METHOD] Data from the five-year registration in the Cerebral Palsy Registry of Norway were used to investigate the proportion of children with cerebral palsy born in the period 1999-2010 treated with botulinum toxin A, and whether there were any variations in the proportion of children treated between the habilitation centres. We conducted an online survey to identify the treatment guidelines that were applied in all of the 21 habilitation centres.
[RESULTS] A total of 1 414 children (average age 6.3 years) were included, of whom 775 (55 %) had been treated with botulinum toxin A. The proportion of children who received treatment varied considerably between the habilitation centres (38-80 %; p < 0.001). The maximum dose of botulinum toxin A per treatment per patient was 200-600 units of Botox. Five centres reported to have written guidelines for the treatment indication.
[INTERPRETATION] The proportion of children with cerebral palsy who are treated with botulinum toxin A varies considerably between Norwegian habilitation centres.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 6 | |
| 시술 | botox
|
보툴리눔독소 주사 | dict | 1 |
MeSH Terms
Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Cross-Sectional Studies; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Neuromuscular Agents; Norway; Orthopedic Procedures; Practice Guidelines as Topic; Registries; Rehabilitation Centers; Surveys and Questionnaires
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
같은 제1저자의 인용 많은 논문 (1)
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.